Skip to main content

Table 1 Study characteristics

From: Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis

Part A      
Study Population Inhaled drug treatment Treatment duration (months) Definition of exacerbation Severity of exacerbation
Baumgartner et al 2007 [48] n = 433 (58% males)
Mean age in years: 63
Mean FEV1: 41% predicted
Group 1: Salmeterol 42 μg bid
Group 2: Formoterol 25 μg bid
Group 3: Placebo
3 Event-based Moderate and severe
Beeh et al 2006 [21] n = 1639 (76% males)
Mean age in years: 62
Mean FEV1: 45% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Placebo
3 Event-based Moderate and severe
Bourbeau et al 1998 [22] n = 79 (66% males)
Mean age in years: 66
Mean FEV1: 43% predicted
Group 1: Budesonide 800 μg bid
Group 2: Placebo
6 Event-based Moderate and severe
Boyd et al 1997[23] n = 445 (79% males)
Mean age in years: 62
Mean FEV1: ≈65% predicted (only FEV1 in liters reported)
Group 1: Salmeterol 50 μg bid
Group 2: Placebo
3.5 Event-based Moderate and severe
Briggs et al 2005[49] n = 653 (66% males)
Mean age in years: 64
Mean FEV1: 38% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Salmeterol 50 μg bid
3 Symptom-based Moderate and severe
Brusasco et al 2003 [24, 35] n = 1207 (76% males)
Mean age in years: 64
Mean FEV1: 38% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Salmeterol 50 μg bid
Group3: Placebo
6 Symptom-based Moderate and severe
Burge et al 2000 [25] n = 742 (75% males)
Mean age in years: 64
Mean FEV1: 50% predicted
Group 1: Fluticasone 500 μg bid
Group 2: Placebo
36 Event-based Moderate and severe
Calverley et al 2003 [26] n = 1465 (76% males)
Mean age in years: 63
Mean FEV1: 45% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Fluticasone 500 μg bid
Group 3: Salmeterol 50 μg bid + Fluticasone 500 μg bid
Group 4: Placebo
12 Event-based Moderate and severe
Part B      
Calverley et al 2003 [27] n = 1022 (73% males)
Mean age in years: 64
Mean FEV1: 36% predicted
Group 1: Formoterol 9 μg bid
Group 2: Budesonide 400 μg bid
Group 3: Formoterol 9 μg bid + Budesonide 320 μg bid
Group 4: Placebo
12 Event-based Moderate and severe
Calverley et al 2003 [28] n = 78 (60% males)
Mean age in years: 65
Mean FEV1: 40% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Placebo
6 Event-based Moderate and severe
Calverley et al 2007 [14] n = 6112 (76% males)
Mean age in years: 65
Mean FEV1: 44% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Fluticasone 500 μg bid
Group 3: Salmeterol 50 μg bid + Fluticasone 500 μg bid
Group 4: Placebo
36 Event-based Severe
Campbell et al 2005 [29] n = 432 (67% males)
Mean age in years: 60
Mean FEV1: 54% predicted
Group 1: Formoterol 9 μg bid
Group 2: Placebo
6 Event-based Moderate and severe
Casaburi et al 2002 [50] n = 921 (65% males)
Mean age in years: 65
Mean FEV1: 36% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Placebo
12 Symptom-based Moderate and severe
Celli et al 2003 [30] n = 824 (70% males)
Mean age in years: 64
Mean FEV1: 42% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Placebo
3 Event-based Moderate and severe
Chapman et al 2002 [31] n = 408 (64% males)
Mean age: not reported
Mean FEV1: 45% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Placebo
5.5 Event-based Moderate and severe
Covelli et al 2004 [32] n = 196 (66% males)
Mean age in years: 65
Mean FEV1: 40% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Placebo
3 Symptom-based Moderate and severe
Part C      
Dahl et al 2001 [33] n = 392 (75% males)
Mean age in years: 64
Mean FEV1: 45% predicted
Group 1: Formoterol 24 μg bid
Group 2: Placebo
3 Event-based Severe
Dusser et al 2006 [34] n = 1010 (88% males)
Mean age in years: 65
Mean FEV1: 48% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Placebo
12 Event-based Moderate and severe
Hanania et al 2003 [51] n = 540 (63% males)
Mean age in years: 64
Mean FEV1: 42% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Fluticasone 250 μg bid
Group 3: Salmeterol 50 μg bid + Fluticasone 250 μg bid
Group 4: Placebo
5.5 Event-based Moderate and severe
Kardos et al 2007 [52] n = 994 (76% males)
Mean age in years: 64
Mean FEV1: 40% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Salmeterol 50 μg bid + Fluticasone 500 μg bid
10 Event-based Moderate and severe
Littner et al 2000 [36] n = 68 (65% males)
Mean age in years: 66
Mean FEV1: 42% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Placebo
1 Symptom-based Moderate and severe
Mahler et al 1999 [37] n = 278 (74% males)
Mean age in years: 63
Mean FEV1: 40% predicted
Group 1: Salmeterol 42 μg bid
Group 2: Placebo
3 Symptom-based Moderate and severe
Mahler et al 2002 [38] n = 671 (66% males)
Mean age in years: 64
Mean FEV1: 41% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Fluticasone 500 μg bid
Group 3: Salmeterol 50 μg bid + Fluticasone 500 μg bid
Group 4: Placebo
5.5 Event-based Moderate and severe
Part D      
Niewoehner et al 2005 [39] n = 1829 (99% males)
Mean age in years: 68
Mean FEV1: 36% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Placebo
6 Event-based Moderate and severe
Paggiaro et al 1998 [40] n = 281 (74% males)
Mean age in years: 63
Mean FEV1: 57% predicted
Group 1: Fluticasone 500 μg bid
Group 2: Placebo
12 Event-based Moderate and severe
Paggiaro et al 2006 [41] n = 114 (73% males)
Mean age in years: 66
Mean FEV1: 53% predicted
Group 1: Flunisolide 1 mg bid
Group 2: Placebo
6 Event-based Moderate and severe
Rossi 2002[42] n = 434 (84% males)
Mean age in years: 63
Mean FEV1: 47% predicted
Group 1: Formoterol 25 μg bid
Group 2: Placebo
3 Event-based Moderate and severe
Stockley et al 2006 [43] n = 634 (76% males)
Mean age in years: 62
Mean FEV1: 46% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Placebo
12 Event-based Moderate and severe
Szafranski et al 2000 [44] n = 812 (79% males)
Mean age in years: 64
Mean FEV1: 36% predicted
Group 1: Formoterol 4.5 μg bid
Group 2: Budesonide 200 μg bid
Group 3: Formoterol 4.5 μg bid + Budesonide 160 μg bid
Group 4: Placebo
12 Event-based Moderate and severe
Van der Valk et al 2002 [45] n = 244 (84% males)
Mean age in years: 64
Mean FEV1: 57% predicted
Group 1: Fluticasone 500 μg bid
Group 2: Placebo
5.5 Event-based Moderate and severe
Part E      
Van Noord et al 2000 [46] n = 92 (88% males)
Mean age in years: 65
Mean FEV1: 41% predicted
Group 1: Salmeterol 50 μg bid
Group 2: Placebo
3 Event-based Moderate and severe
Wadbo et al 2002 [47] n = 121 (53% males)
Mean age in years: 64
Mean FEV1: 33% predicted
Group 1: Formoterol 18 μg bid
Group 2: Placebo
3 Symptom-based Moderate and severe
Wedzicha et al 2008 [53] n = 1323 (83% males)
Mean age in years: 64
Mean FEV1: 39% predicted
Group 1: Tiotropium 18 μg qd
Group 2: Salmeterol 50 μg bid + Fluticasone 500 μg bid
24 Event-based Moderate and severe
Weir et al 1999 [54] n = 98 (72% males)
Mean age in years: 66
Mean FEV1: not reported
Group 1: Beclomethasone 750–1000 μg bid
Group 2: Placebo
5.5 Symptom-based Moderate and severe